Skip to content
Review Open access

Deciphering the pulmonary fibrosis niche: A single-cell transcriptomic perspective on cellular crosstalk and microenvironment remodeling.

Aug 2026 · Cytokine & growth factor reviews · Vol 91, pp. 150-160 · 0 citations · 49 references
Medicine

TL;DR

This review synthesizes the emerging single-cell and spatial atlas of human PF/ILD into a framework for molecular subtyping and precision medicine, arguing that the future of IPF therapy lies in disrupting specific niche communication axes rather than broadly antagonizing collagen synthesis.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal interstitial lung disease driven by aberrant repair after repetitive alveolar micro-injury. The classical paradigm - that fibrosis is a passive consequence of epithelial injury followed by fibroblast activation - has been substantially reshaped by single-cell RNA sequencing (scRNA-seq) and, more recently, spatial transcriptomics. These technologies have resolved the lung into a constellation of molecularly distinct cell states and exposed a highly structured fibrotic niche in which epithelial, mesenchymal, immune, and endothelial compartments are engaged in active, ligand-receptor-mediated crosstalk. This review synthesizes the emerging single-cell and spatial atlas of human PF/ILD, with a focus on four themes: (i) the ectopic KRT5⁻/KRT17⁺ aberrant basaloid epithelium and the persistence of a KRT8⁺ alveolar differentiation intermediate; (ii) the lipofibroblast-to-myofibroblast trajectory and the collagen-producing fibroblast atlas that explains heterogeneous drug response; (iii) immune remodeling, particularly the metabolic reprogramming of SPP1⁺/MERTK⁺ macrophages and the exhaustion of CD8⁺ T cells; and (iv) the spatial organization of disease-associated niches at the fibroblast-focus edge. We then translate these findings into a framework for molecular subtyping and precision medicine, arguing that the future of IPF therapy lies in disrupting specific niche communication axes rather than broadly antagonizing collagen synthesis. Beyond cataloguing cell types, we emphasize the systems-level principle that emerges from the single-cell literature: IPF is not a disease of one cell type gone wrong, but a disease of the communication network that binds multiple compartments into a self-sustaining, maladaptive ecosystem.

Read PDF

Similar papers

Review Open access Sep 2026

Reconfiguring the macrophage-centric intercellular network in pulmonary fibrosis: Emerging perspectives and therapeutic opportunities.

Pulmonary fibrosis (PF) encompasses a spectrum of progressive and irreversible interstitial lung diseases characterized by a notably poor prognosis. The principal pathological features of PF include recurrent injury to the alveolar epithelium, aberrant accumulation of extracellular matrix (ECM) components, and disrupti...

Yu-Jie Yang, Sen-Yuan Liu, Shang-Xuan Wang et al. · 0 citations
Review Open access Oct 2026

The Shared Pathological Niche in Pulmonary Fibrosis: From Aberrant Epithelial Repair to ECM Remodeling

Pulmonary fibrosis is a frequent complication of abnormal tissue repair following lung injury by many causes. It can be found in various diseases and clinical conditions, such as idiopathic pulmonary fibrosis, cancer-treatment-induced lung injury, and other occupational, environmental, and autoimmune lung diseases. Tho...

Lu Yang, Yu-Ting Huang, An-Dong Liu et al. · 0 citations
Review Sep 2026

Macrophage heterogeneity in organ fibrosis in the era of single-cell omics

A theoretical basis is provided for understanding the pathogenesis of fibrosis and developing precision treatment strategies based on macrophage heterogeneity, as well as the therapeutic potential of targeting macrophage metabolic pathways, phenotypic transitions, and the elimination of specific subpopulations.

Wen-Hui Qiu, Ying Huang, Jia-Yi Chen et al. · 0 citations
Review Sep 2026

Macrophage-fibroblast communication driven by biomechanical stress in the pulmonary profibrotic niche: From signalling transduction to clinical translation.

Pulmonary (interstitial) fibrosis, the terminal pathological stage of various interstitial lung diseases, remains a major therapeutic challenge. The three approved antifibrotic agents - pirfenidone, nintedanib, and nerandomilast - receive only moderate endorsements in current guidelines, as they decelerate rather than...

Hong Yang, Xing-Yun Hou, Li-Ya Ye et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.